Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 16/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29822173 | 1.00 | P2RX7 (0.40) | P2RX7MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL23168941 | 0.91 | THRB (0.38) | P2RX7MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL23168772 | 0.88 | MAPT (0.43) | P2RX7MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL23168932 | 0.87 | NPBWR1 (0.43) | MAPTKDM4EALDH1A1LMNA | |
| SCHEMBL24819258 | 0.86 | NPBWR1 (0.39) | P2RX7POLBALDH1A1 | |
| SCHEMBL23168748 | 0.84 | P2RX7 (0.37) | P2RX7MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL23168951 | 0.84 | MAPT (0.40) | P2RX7MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL31356395 | 0.84 | MAPT (0.40) | P2RX7MAPTCYP1A2POLBCYP3A4 | |
| SCHEMBL23168653 | 0.83 | MAPT (0.47) | P2RX7MAPTLMNAKMT2A | |
| SCHEMBL29821821 | 0.83 | MAPT (0.47) | P2RX7MAPTLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| WO-2021057791-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | 广东东阳光药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411400-A1 | CHEMICAL COMPOUND AS THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | P2RX7 1050/4885MAPT 1873/4885CYP1A2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.